/
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities in…
The business is unprofitable at the operating level (-18478.46% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 132.1% YoY with margins expanding 11964.4pp.
ROIC dropped from -262.38% to -857.73%, capital efficiency is deteriorating. Negative free cash flow of -$18M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$130K
▲ +132.1% YoY
Net Income (TTM)
-$21M
▼ -72.2% YoY
Op. Margin
-18478.46%
▲ +11964.4pp YoY
ROIC
-857.73%
▼ -595.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$18M
▼ -5.0% YoY
Op. Cash Flow (TTM)
-$18M
▼ -4.8% YoY
Net Debt
-$21M
Net Cash Position
Cash & Equiv.
$25M
5Y CAGR: -18.5%
Continue Research